Cytek Biosciences, Inc.

Cytek Biosciences, Inc.

CTKBยทNASDAQ

$4.05

-3.3%
HealthcareMedical - Devices

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system, which leverages full spectrum profiling technology to further broaden potential applications across cell analysis. The company also provides reagents and kits, including cFluor reagents, which are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, which are automated plate loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific region; and through distributors or sales agents in European, Latin American, the Middle Eastern, and the Asia-Pacific countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.

At a Glance

Live Snapshot
Market Cap$523.03M
EPS-0.5200
P/E Ratio-7.79
Earnings Date08/05/2026
3Y+23.0%
5Y+117.0%
10Y+248.0%
3Y-2683.0%
5Y-443.0%
10Y+295.0%
3Y-62.0%
5Y-131.0%
10Y-66.0%
Cytek Biosciences, Inc.

Cytek Biosciences, Inc. Profit Bridge

CTKB ยท NASDAQ
Revenue201.49M
Cost of Goods Sold (97.03M)
Gross Profit104.46M
Operating Expenses (144.84M)
Operating Income-40.38M
Interest Expense (474.00K)
Other Income/Expense10.54M
Pretax Income-29.84M
Income Tax (36.70M)
Net Income-66.54M
Net Income
-66.54M

Profitability Analysis

Gross Margin

51.8%

Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.

Operating Margin

-20.0%

Operating losses indicate the core business is unprofitable. Requires restructuring or revenue growth.

Net Profit Margin

-33.0%

Net losses indicate the company is burning cash. Sustainability depends on path to profitability.

Profitability Insight

Margin squeeze alert: Healthy gross margins but weak operating margins suggest excessive operating expenses. Cost optimization could unlock significant value.

Cytek Biosciences, Inc. Income Statement

CTKB โ€ข NASDAQ

Cytek Biosciences, Inc. Income StatementDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
REVENUE
201.5M
200.5M
193M
164M
128M
92.8M
57.9M
GROSS PROFIT
(97M)
(89.3M)
(83.6M)
(63.1M)
(48.8M)
(41.1M)
(29.2M)
104.5M
111.1M
109.4M
101M
79.1M
51.7M
28.7M
OPERATING INCOME
(144.8M)
(131.6M)
(137.3M)
(102.8M)
(70M)
(38.1M)
(45.9M)
(108.4M)
(92.2M)
(93.1M)
(67.9M)
(45.5M)
(24.4M)
(17M)
(36.5M)
(39.4M)
(44.2M)
(34.9M)
(24.4M)
(13.7M)
(8.9M)
-40.4M
-20.5M
-27.8M
-1.8M
9.2M
13.7M
-17.3M
PRE-TAX INCOME
(474K)
(0.0)
(2.1M)
(2.6M)
(1.7M)
(333K)
(1K)
1.7M
10.4M
4.3M
2M
-1.7M
-223K
710K
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(20M)
10.5M
14.8M
12.1M
3.1M
-3.2M
771K
962K
-29.8M
-5.7M
-15.7M
1.3M
5.9M
14.4M
-16.3M
NET INCOME
(36.7M)
(320K)
-3.6M
-1.2M
(2.9M)
-5M
(533K)
-66.5M
-6M
-12.1M
2.6M
3M
19.4M
-16.8M

SEC Filings

CTKB - Filing history and reports

Filing TypeFiling DatePeriod EndingFiscal YearActions
8-K

8-K 2026

N/A

June 02, 2026
May 27, 2026
2026
10-Q

10-Q 2026 Q1

Q1

May 07, 2026
March 31, 2026
2026
8-K

8-K 2026

N/A

May 07, 2026
May 07, 2026
2026
DEF 14A

DEF 14A 2026

N/A

April 28, 2026
June 10, 2026
2026
10-K

10-K 2025 FY

FY

February 26, 2026
December 31, 2025
2025
8-K

8-K 2026

N/A

February 26, 2026
February 26, 2026
2026
8-K

8-K 2026

N/A

January 13, 2026
January 12, 2026
2026
10-Q

10-Q 2025 Q3

Q3

November 05, 2025
September 30, 2025
2025
8-K

8-K 2025

N/A

November 05, 2025
November 05, 2025
2025
8-K

8-K 2025

N/A

August 06, 2025
August 06, 2025
2025
Showing 1 to 10 of 70 filings